Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug;42(1):111-9.
doi: 10.1007/s12160-011-9271-3.

Sexual HIV transmission and antiretroviral therapy: a prospective cohort study of behavioral risk factors among men and women living with HIV/AIDS

Seth C Kalichman  1 , Chauncey Cherry, Denise White, Miche'l Jones, Tamar Grebler, Moira O Kalichman, Mervi Detorio, Angela M Caliendo, Raymond F Schinazi
Affiliations

Sexual HIV transmission and antiretroviral therapy: a prospective cohort study of behavioral risk factors among men and women living with HIV/AIDS

Seth C Kalichman et al. Ann Behav Med. 2011 Aug.

Abstract

Background: Using antiretroviral therapies for HIV prevention relies on patient adherence and avoidance of co-occurring sexually transmitted infections.

Purpose: The objective of this study is to simultaneously examine HIV treatment adherence and sexual risks for HIV transmission.

Methods: This study is a prospective cohort of 201 men and 55 women diagnosed with HIV/AIDS infection.

Results: A total of 32% men and 39% women engaged in unprotected intercourse with at least one HIV negative or unknown HIV status sex partner over 12 months. Nearly half (46%) of participants with HIV negative or unknown HIV status unprotected sex partners had detectable HIV viral load and were significantly more likely to have contracted a sexually transmitted infection since their HIV diagnosis. Individuals at higher risk for transmitting HIV were also less adherent to antiretroviral therapies.

Conclusions: Programs that aim to use antiretroviral therapies for HIV prevention require careful attention to adherence, sexually transmitted co-infections, and substance use.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement The authors have no conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1
Antiretroviral therapy adherence monitored by unannounced pill counts over 8 months for participants at lower and higher HIV transmission risk who drink alcohol and those who do not drink
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kalichman SC. Time to take stock in HIV/AIDS prevention. AIDS Behav, 2008; 12(3): p. 333–4. - PubMed
    1. Grant RM, Lama JR, Anderson PL et al., Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Eng J Med, 2010; November 23, 2010. - PMC - PubMed
    1. Kashuba AD, Dyer JR, Kramer L, Raasch R, Eron J, Cohen M. Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemotherther, 1999;43(8): 1817–26. - PMC - PubMed
    1. Donnell D, Baeteb JM, Kiarie J, Thomas K, Stevens W, Cohen C, MCIntyre J, Lingappa J, Celum C. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: A prospective cohort analysis. Lancet 2010;375:2092–98. - PMC - PubMed
    1. Quinn TC, Wawer M, Sewankambo MB, Serwadda D, Li C, Wabwire-Mangen F, et al. et al., Viral load and heterosexual transmission of human immunodeficiency virus type 1. New England Journal of Medicine, 2000; 342: 921–929. - PubMed

Publication types

MeSH terms

Substances